

EMA regulatory perspective on ISCTM Session 3B: Neuroinflammation and CNS Disorders: Construct to potential treatments

Elena Hernandez Martinez de Lapiscina & Florence Butlen Office of Therapies for neurological and psychiatric disorders (H-NEU) European Medicines Agency





Disclaimer

The views expressed in this presentation are **the personal views of the author**(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties.